[104]
Dr. Klibanov maintains that the process for the isolation or resolution of the ofloxacin enantiomers would not inevitably be apparent from the '840 patent, and would in fact be difficult to determine. Further, the beneficial properties of the S(-) optical isomer of ofloxacin would not be known from any of the pieces of prior art cited by Novopharm as anticipatory.